RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Ongoing long-term studies from the two major producers of transcatheter aortic valve replacements showed the minimally invasive route can continue to perform on par with open-heart surgery in a ...

Edwards Lifesciences, a medical technology company based in the US, has announced the complete acquisition of Innovalve Bio Medical, which specialises in transcatheter heart valve devices. The ...

Heart disease remains the leading cause of death in the United States, but advances in medical technology are giving patients ...

WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...

SAN FRANCISCO, March 11 (Reuters) - Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three ...

Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...

Transcatheter aortic valve replacement (TAVR) is a procedure that can treat narrowing of the aortic valve in the heart. It involves an expandable replacement valve that helps improve blood flow. A ...

Please provide your email address to receive an email when new articles are posted on . Patients who underwent a second transcatheter aortic valve replacement had outcomes similar to those with a ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...